Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior

Oncotarget

Volumn 7, Issue 32, 2016, Pages 52003-52016

  Ferreira, Luciana Bueno ^a,b   Tavares, Catarina ^a,b   Pestana, Ana ^a,b   Pereira, Catarina Leite ^a,b,e   Eloy, Catarina ^b   Pinto, Marta Teixeira ^a,b   Castro, Patricia ^a,b,d   Batista, Rui ^a,b   Rios, Elisabete ^a,b,c,d   Sobrinho Simões, Manuel ^a,b,c,d   Pereira Gimba, Etel Rodrigues ^f,g   Soares, Paula ^a,b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^f INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^g FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Invasion; Migration; Osteopontin splice variants (OPN SV); Osteopontin a (OPNa); Thyroid cancer

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; OSTEOPONTIN; ISOPROTEIN; SPP1 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAF GENE; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PROTEIN EXPRESSION; PROTEIN SECRETION; THYROID CARCINOMA; TUMOR VOLUME; METABOLISM; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR; TUMOR INVASION;

CARCINOMA, PAPILLARY; HUMANS; NEOPLASM INVASIVENESS; OSTEOPONTIN; PROTEIN ISOFORMS; THYROID NEOPLASMS;

EID: 84982293109     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10468     Document Type: Article

References (54)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010 CA Cancer J Clin. 2010; 60:277-300.
2. Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. Journal of cancer epidemiology. 2013; 2013:965212.
3. Davies L and Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama. 2006; 295:2164-2167.
4. Grodski S, Brown T, Sidhu S, Gill A, Robinson B, Learoyd D, Sywak M, Reeve T and Delbridge L. Increasing incidence of thyroid cancer is due to increased pathologic detection. Surgery. 2008; 144:1038-1043; discussion 1043.
5. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE and Devesa SS. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009; 18:784-791.
6. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL and Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne. 2007; 177:1357-1361.
7. Simard EP, Ward EM, Siegel R and Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA: a cancer journal for clinicians. 2012; 62:118-128.
8. Aschebrook-Kilfoy B, Ward MH, Sabra MM and Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2011; 21:125-134.
9. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet. 2002; 360:1131-1135.
10. Burningham AR, Krishnan J, Davidson BJ, Ringel MD and Burman KD. Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy. Otolaryngol Head Neck Surg. 2005; 132:840-844.
11. Carneiro RM, Carneiro BA, Agulnik M, Kopp PA and Giles FJ. Targeted therapies in advanced differentiated thyroid cancer. Cancer treatment reviews. 2015; 41:690-698.
12. Denhardt DT and Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993; 7:1475-1482.
13. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM and Santoro M. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab. 2005; 90:5270-5278.
14. Sun Y, Fang S, Dong H, Zhao C, Yang Z, Li P and Wang J. Correlation between osteopontin messenger RNA expression and microcalcification shown on sonography in papillary thyroid carcinoma. J Ultrasound Med. 2011; 30:765-771.
15. Briese J, Cheng S, Ezzat S, Liu W, Winer D, Wagener C, Bamberger AM and Asa SL. Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Res. 2010; 30:1681-1688.
16. Kang KH. Osteopontin expression in papillary thyroid carcinoma and its relationship with the BRAF mutation and tumor characteristics. J Korean Surg Soc. 2013; 84:9-17.
17. Wafaey Gomaaa MA-A, Osman Hamourd, Jaudah Al-Maghrabia. Osteopontin cytoplasmic immunoexpression is a predictor of poor disease-free survival in thyroid cancer. Journal of Microscopy and Ultrastructure. 2013; 1:8-16.
18. Wai PY and Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer metastasis reviews. 2008; 27:103-118.
19. Rittling SR and Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004; 90:1877-1881.
20. Murphy G and Gavrilovic J. Proteolysis and cell migration: creating a path? Current opinion in cell biology. 1999; 11:614-621.
21. Shevde LA and Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014; 37:131-141.
22. Xu K, Tian X, Oh SY, Movassaghi M, Naber SP, Kuperwasser C and Buchsbaum RJ. The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis. Breast cancer research: BCR. 2016; 18:14.
23. Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW and Fisher LW. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics. 1990; 7:491-502.
24. Anborgh PH, Mutrie JC, Tuck AB and Chambers AF. Pre-and post-translational regulation of osteopontin in cancer. Journal of cell communication and signaling. 2011; 5:111-122.
25. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI and Kim KW. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol. 2009; 35:1409-1416.
26. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF and Gimba ER. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 2011; 9:280-293.
27. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016.
28. Subraman V, Thiyagarajan M, Malathi N and Rajan ST. OPN-Revisited. J Clin Diagn Res. 2015; 9:ZE10-13.
29. Kusafuka K, Yamaguchi A, Kayano T and Takemura T. Expression of bone matrix proteins, osteonectin and osteopontin, in salivary pleomorphic adenomas. Pathology, research and practice. 1999; 195:733-739.
30. Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clement B and Coulouarn C. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology. 2013; 58:1992-2000.
31. Bhowmick NA and Moses HL. Tumor-stroma interactions. Current opinion in genetics & development. 2005; 15:97-101.
32. Kim JB, Stein R and O'Hare MJ. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol. 2005; 26:173-185.
33. Patani N, Jouhra F, Jiang W and Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer research. 2008; 28:4105-4110.
34. Tang X, Li J, Yu B, Su L, Yu Y, Yan M, Liu B and Zhu Z. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. International journal of biological sciences. 2013; 9:55-66.
35. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B and Weber GF. Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008; 122:889-897.
36. Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR and Gimba ER. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol. 2012; 92:13-19.
37. Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, Orringer MB, Reddy RM, Chang AC, Beer DG and Lin L. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget. 2015; 6:22239-22257. doi: 10.18632/oncotarget.4161.
38. Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcene A, Castronovo V and Gimba ER. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate. 2012; 72:1688-1699.
39. TATIANA MARTINS TILLI LBFaERPG. Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling. Oncology Letters. 2015; 9.
40. Nakamura KD, Tilli TM, Wanderley JL, Palumbo A, Jr., Mattos RM, Ferreira AC, Klumb CE, Nasciutti LE and Gimba ER. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumour Biol. 2015.
41. Denhardt D. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005; 124:xvi-xviii.
42. Fedarko NS, Jain A, Karadag A and Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J. 2004; 18:734-736.
43. Rangaswami H, Bulbule A and Kundu GC. Nuclear factorinducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem. 2004; 279:38921-38935.
44. Friedl P and Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nature reviews Cancer. 2003; 3:362-374.
45. Shi Z, Mirza M, Wang B, Kennedy MA and Weber GF. Osteopontin-a alters glucose homeostasis in anchorageindependent breast cancer cells. Cancer letters. 2014; 344:47-53.
46. Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A and Pass HI. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochemical and biophysical research communications. 2009; 382:514-518.
47. Rosai J DRA CM, Frable WJ, Tallini G. (2014). Tumors of the Thyroid & Parathyroid Glands. (Washington DC).
48. Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF and Senger DR. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell. 1992; 3:1169-1180.
49. Ferreira LB, Eloy K, Pestana A, Lyra J, Moura M, Prazeres H, Tavares C, Sobrinho-Simoes M, Gimba ER and Soares P. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. European journal of endocrinology / European Federation of Endocrine Societies. 2016.
50. Meireles AM, Preto A, Rocha AS, Rebocho AP, Maximo V, Pereira-Castro I, Moreira S, Feijao T, Botelho T, Marques R, Trovisco V, Cirnes L, Alves C, Velho S, Soares P and Sobrinho-Simoes M. Molecular and genotypic characterization of human thyroid follicular cell carcinomaderived cell lines. Thyroid. 2007; 17:707-715.
51. He B, Mirza M and Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006; 25:2192-2202.
52. Populo H, Tavares S, Faustino A, Nunes JB, Lopes JM and Soares P. GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. PeerJ. 2013; 1:e104.
53. Cardoso AP, Pinto ML, Pinto AT, Oliveira MI, Pinto MT, Goncalves R, Relvas JB, Figueiredo C, Seruca R, Mantovani A, Mareel M, Barbosa MA and Oliveira MJ. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. Oncogene. 2014; 33:2123-2133.
54. Gomes C, Osorio H, Pinto MT, Campos D, Oliveira MJ and Reis CA. Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PloS one. 2013; 8:e66737.